Clinical trials: Irritable Bowel Syndrome
Irritable Bowel Syndrome With Constipation (IBS-C)
Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C
Irritable bowel syndrome (IBS) is a common functional bowel disorder that imposes a considerable burden on health-related quality of life (QOL) worldwide.
- Trial name
- RELAX (NCT05240521)
- Testing
- ARM A, ARM B
- Where
- 4 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Devintec Sagl
Irritable Bowel Syndrome With Diarrhea
A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
This study will evaluate the effects of ORP-101 versus placebo on stool consistency and abdominal pain in patients with Irritable Bowel Syndrome with Diarrhea (IBS-D).
- Trial name
- NCT04129619
- Testing
- ORP-101
- Where
- 74 sites in United States
- Volunteers
- 321 people
- Sponsor
- OrphoMed, Inc.
Constipation-predominant Irritable Bowel Syndrome
Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype
The main objective is to assess the effect of an 8-week daily supplementation with IbSium® (probiotic yeast Saccharomyces cerevisiae CNCM I-3856) on the improvement gastro-intestinal disorders associated to the type C IBS…
- Trial name
- IBS-GO (NCT03150212)
- Testing
- Saccharomyces cerevisiae CNCM I-3856
- Where
- 5 sites in France
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Lesaffre International
Irritable Bowel Syndrome
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts.
- Trial name
- BALANCE (NCT07519395)
- Testing
- Camlipixant
- Where
- 114 sites in United States
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
Gastrointestinal Symptoms in Healthy Subjects and Patients With Irritable Bowel Syndrome
The aim of this study performed in Irritable Bowel Syndrome (IBS) subjects and healthy patients is to demonstrate the ability of composite score of frequency of gastrointestinal symptoms to discriminate healthy subjects and IBS…
- Trial name
- NCT01457378
- Where
- 2 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
Irritable Bowel Syndrome Characterized by Constipation
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
The objective of this trial is to determine the effect of linaclotide on abdominal girth in IBS-C participants with the baseline symptoms of abdominal bloating and an increased abdominal girth.
- Trial name
- NCT02837783
- Testing
- Linaclotide
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
This clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo.
- Trial name
- D5630C00001 (NCT01880424)
- Testing
- Linaclotide
- Where
- 82 sites in United States, Australia and 3 more
- Volunteers
- 1,722 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome (IBS)
A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers
This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.
- Trial name
- NCT00401479
- Testing
- Solabegron (GW427353)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Inflammatory Bowel Diseases, Irritable Bowel Syndrome
Fecal Calprotectin Collection Protocol
The primary objective is to obtain stool samples from subjects diagnosed with , and displaying signs and/or symptoms of IBD and/or IBS will be evaluated in this study.
- Conditions
- Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease
- Trial name
- CALFE (NCT03143517)
- Testing
- Stool collection
- Where
- 13 sites in United States
- Volunteers
- 240 people
- Sponsor
- DiaSorin Inc.
Irritable Bowel Syndrome
A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects
The current study is designed to assess the safety, tolerability, pharmacokinetics (PK), gastrointestinal (GI) transit time and pharmacodynamic (PD) biomarkers of repeat oral doses of GSK3179106 administered for 14 days in normal…
- Trial name
- NCT02798991
- Testing
- GSK3179106
- Where
- Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects
The purpose of this study is to assess the pharmacodynamic effects, pharmacokinetics, and safety of two oral formulations (tablet and capsule) of LX1033 in normal healthy volunteers.
- Trial name
- NCT01411800
- Testing
- 250 mg capsule, 250 mg tablets
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Irritable Bowel Syndrome
The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome
To demonstrate benefit of a probiotic product in adults with irritable bowel syndrome.
- Trial name
- NCT02108119
- Testing
- Probiotics
- Where
- Netherlands
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Probi AB
Irritable Bowel Syndrome
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study.
- Trial name
- NCT06206265
- Testing
- TRYP-0082, Psychotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- TRYP Therapeutics
Irritable Bowel Syndrome
Pain Relief In Irritable Bowel Syndrome
The purpose of this study is to determine whether Proklama is effective in significative reduction of pain, other symptoms IBS's related, and improves quality of life concerning IBS disease.
- Trial name
- PRITON (NCT02573844)
- Testing
- Proklama
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Geophyt S.r.l.s.
Irritable Bowel Syndrome, IBS
Study of Bacteria on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome
The purpose of this study is to determine whether probiotic bacterium Bifidobacterium longum (B. longum) can improve mood and bowel symptoms in patients with Irritable bowel syndrome (IBS).
- Trial name
- NCT01276626
- Testing
- Bifidobacterium longum, Maltodextrin
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Société des Produits Nestlé (SPN)
IBS (Irritable Bowel Syndrome), Bloating
A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating
This study is a randomized, double-blind, placebo-controlled, within-individual crossover trial designed to assess the impact of regular use of a consumer-grade FODMAP-targeting digestive enzyme blend (FODZYME®) on…
- Conditions
- IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
- Trial name
- NCT07591584
- Testing
- FODMAP-targeting digestive enzyme blend
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Kiwi Health Inc
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 2 (NCT00724126)
- Testing
- Rifaximin
- Where
- 88 sites in United States
- Volunteers
- 637 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
A Study of BMS-562086 in Patients With Irritable Bowel Syndrome
The primary purpose of this study is to evaluate the effects of BMS-562086 on small bowel and colonic transits in female subjects with diarrhea-predominant irritable bowel syndrome (D-IBS)
- Trial name
- NCT00399438
- Testing
- BMS-562086
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Irritable Bowel Syndrome Characterized by Constipation
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with IBS-C.
- Trial name
- NCT03573908
- Testing
- Linaclotide
- Where
- 79 sites in United States
- Volunteers
- 614 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Diarrhea-predominant Irritable Bowel Syndrome
Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D
The objective of this study is to evaluate the safety and efficacy Rifamycin SV-MMX® 600 mg tablets for patients with diarrhoea-predominant irritable bowel syndrome when administered two to three times daily.
- Trial name
- NCT03099785
- Testing
- Rifamycin SV 600mg t.i.d.
- Where
- 29 sites in Belgium, Germany and 2 more
- Volunteers
- 279 people
- Sponsor
- Cosmo Technologies Ltd